First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

NCT00982111 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

633

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Pemetrexed
DRUG: Cisplatin
BIOLOGICAL: Necitumumab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]